CN113170898A - Health-care composition assisting in reducing blood sugar and blood fat and health-care product thereof - Google Patents
Health-care composition assisting in reducing blood sugar and blood fat and health-care product thereof Download PDFInfo
- Publication number
- CN113170898A CN113170898A CN202110490012.7A CN202110490012A CN113170898A CN 113170898 A CN113170898 A CN 113170898A CN 202110490012 A CN202110490012 A CN 202110490012A CN 113170898 A CN113170898 A CN 113170898A
- Authority
- CN
- China
- Prior art keywords
- vitamin
- parts
- health
- spider silk
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004369 blood Anatomy 0.000 title claims abstract description 61
- 239000008280 blood Substances 0.000 title claims abstract description 61
- 239000000203 mixture Substances 0.000 title claims abstract description 30
- 230000001603 reducing effect Effects 0.000 title claims abstract description 22
- 229920001872 Spider silk Polymers 0.000 claims abstract description 35
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 32
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 32
- 229920001184 polypeptide Polymers 0.000 claims abstract description 30
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 26
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 26
- 230000036541 health Effects 0.000 claims abstract description 23
- 229940046374 chromium picolinate Drugs 0.000 claims abstract description 20
- GJYSUGXFENSLOO-UHFFFAOYSA-N chromium;pyridine-2-carboxylic acid Chemical compound [Cr].OC(=O)C1=CC=CC=N1.OC(=O)C1=CC=CC=N1.OC(=O)C1=CC=CC=N1 GJYSUGXFENSLOO-UHFFFAOYSA-N 0.000 claims abstract description 20
- LJAOOBNHPFKCDR-UHFFFAOYSA-K chromium(3+) trichloride hexahydrate Chemical compound O.O.O.O.O.O.[Cl-].[Cl-].[Cl-].[Cr+3] LJAOOBNHPFKCDR-UHFFFAOYSA-K 0.000 claims abstract description 18
- 230000000694 effects Effects 0.000 claims abstract description 15
- 239000000047 product Substances 0.000 claims description 22
- 230000029087 digestion Effects 0.000 claims description 17
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 16
- 239000003795 chemical substances by application Substances 0.000 claims description 10
- 229940085493 magnesium amino acid chelate Drugs 0.000 claims description 10
- 239000000395 magnesium oxide Substances 0.000 claims description 10
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 claims description 10
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical group [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 10
- 239000011782 vitamin Substances 0.000 claims description 10
- 229940088594 vitamin Drugs 0.000 claims description 10
- 229930003231 vitamin Natural products 0.000 claims description 10
- 235000013343 vitamin Nutrition 0.000 claims description 10
- UOXSXMSTSYWNMH-UHFFFAOYSA-L zinc;2-aminoacetate Chemical group [Zn+2].NCC([O-])=O.NCC([O-])=O UOXSXMSTSYWNMH-UHFFFAOYSA-L 0.000 claims description 10
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 8
- 229960000304 folic acid Drugs 0.000 claims description 8
- 235000019152 folic acid Nutrition 0.000 claims description 8
- 239000011724 folic acid Substances 0.000 claims description 8
- 239000011691 vitamin B1 Substances 0.000 claims description 8
- 239000011715 vitamin B12 Substances 0.000 claims description 8
- 239000011716 vitamin B2 Substances 0.000 claims description 8
- 239000011708 vitamin B3 Substances 0.000 claims description 8
- 239000011675 vitamin B5 Substances 0.000 claims description 8
- 239000011647 vitamin D3 Substances 0.000 claims description 8
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 7
- 108010009736 Protein Hydrolysates Proteins 0.000 claims description 7
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 7
- 239000011777 magnesium Substances 0.000 claims description 7
- 229910052749 magnesium Inorganic materials 0.000 claims description 7
- 239000003531 protein hydrolysate Substances 0.000 claims description 7
- 239000011726 vitamin B6 Substances 0.000 claims description 7
- 239000011701 zinc Substances 0.000 claims description 7
- 229910052725 zinc Inorganic materials 0.000 claims description 7
- 239000002994 raw material Substances 0.000 claims description 6
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 229910017604 nitric acid Inorganic materials 0.000 claims description 3
- 239000011718 vitamin C Substances 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 2
- 238000001816 cooling Methods 0.000 claims description 2
- 239000000706 filtrate Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- FGHSTPNOXKDLKU-UHFFFAOYSA-N nitric acid;hydrate Chemical compound O.O[N+]([O-])=O FGHSTPNOXKDLKU-UHFFFAOYSA-N 0.000 claims description 2
- 239000006072 paste Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 150000003384 small molecules Chemical class 0.000 claims description 2
- 239000002417 nutraceutical Substances 0.000 claims 3
- 235000021436 nutraceutical agent Nutrition 0.000 claims 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims 1
- 229930003268 Vitamin C Natural products 0.000 claims 1
- 235000013402 health food Nutrition 0.000 claims 1
- 235000019154 vitamin C Nutrition 0.000 claims 1
- 230000002195 synergetic effect Effects 0.000 abstract description 3
- 150000002632 lipids Chemical class 0.000 abstract description 2
- 241000700159 Rattus Species 0.000 description 11
- 230000000052 comparative effect Effects 0.000 description 10
- 206010012601 diabetes mellitus Diseases 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 239000011651 chromium Substances 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- 235000020927 12-h fasting Nutrition 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 235000014590 basal diet Nutrition 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 4
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- 108010028554 LDL Cholesterol Proteins 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 2
- 102000002322 Egg Proteins Human genes 0.000 description 2
- 108010000912 Egg Proteins Proteins 0.000 description 2
- 108010023302 HDL Cholesterol Proteins 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 229910052804 chromium Inorganic materials 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 235000013345 egg yolk Nutrition 0.000 description 2
- 210000002969 egg yolk Anatomy 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 230000004089 microcirculation Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- NRHMKIHPTBHXPF-TUJRSCDTSA-M sodium cholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 NRHMKIHPTBHXPF-TUJRSCDTSA-M 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- FFRBMBIXVSCUFS-UHFFFAOYSA-N 2,4-dinitro-1-naphthol Chemical group C1=CC=C2C(O)=C([N+]([O-])=O)C=C([N+]([O-])=O)C2=C1 FFRBMBIXVSCUFS-UHFFFAOYSA-N 0.000 description 1
- 241000239290 Araneae Species 0.000 description 1
- 241000486627 Chilobrachys guangxiensis Species 0.000 description 1
- 229910021556 Chromium(III) chloride Inorganic materials 0.000 description 1
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- 206010012655 Diabetic complications Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 229960000359 chromic chloride Drugs 0.000 description 1
- QSWDMMVNRMROPK-UHFFFAOYSA-K chromium(3+) trichloride Chemical compound [Cl-].[Cl-].[Cl-].[Cr+3] QSWDMMVNRMROPK-UHFFFAOYSA-K 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 229940127004 drugs for type 2 diabetes Drugs 0.000 description 1
- 230000000081 effect on glucose Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 230000010030 glucose lowering effect Effects 0.000 description 1
- 239000000413 hydrolysate Substances 0.000 description 1
- 230000000055 hyoplipidemic effect Effects 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229960004329 metformin hydrochloride Drugs 0.000 description 1
- OETHQSJEHLVLGH-UHFFFAOYSA-N metformin hydrochloride Chemical compound Cl.CN(C)C(=N)N=C(N)N OETHQSJEHLVLGH-UHFFFAOYSA-N 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin hydrochloride Natural products CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- -1 polytetrafluoroethylene Polymers 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
- 229960002855 simvastatin Drugs 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 201000005665 thrombophilia Diseases 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
- A23L33/155—Vitamins A or D
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
- A23L33/165—Complexes or chelates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to the technical field of health care products, in particular to a health care composition for assisting in reducing blood sugar and blood fat and a health care product thereof. According to the invention, the spider silk hydrolyzed protein polypeptide, the chromium chloride hexahydrate and the chromium picolinate are used in a matching manner, so that the obtained composition has the effects of remarkably assisting in reducing blood sugar and blood fat, is superior to the effects of using two components in pairs, and shows that the combination of the three components produces an obvious synergistic effect. The composition can be used for preparing health product with effects of reducing blood sugar and blood lipid.
Description
Technical Field
The invention relates to the technical field of health-care food, in particular to a health-care composition for assisting in reducing blood sugar and blood fat and a health-care product thereof.
Background
Diabetes is a common frequently-occurring disease seriously harming human health, and at present, more than one hundred million people suffer from diabetes in the world. The fatality rate is second to malignant tumor and cardiovascular disease, and is the third disease endangering human life.
Diabetes mellitus is not cured for life and the complications are wide and serious. Due to the relative or absolute lack of insulin in blood, the metabolic disturbance of sugar, fat and protein is caused, the hyperglycemia, the hyperlipidemia and the blood viscosity are increased, and the wide microvascular lesions of the whole body appear in the middle and late stages. 70-80% of patients die of cardiovascular diseases, and diabetic renal failure and cerebrovascular diseases are common causes of death of middle-aged and elderly diabetic patients. At present, the problems of low curative effect, large effect, secondary failure in later period and the like of the medicine for treating the disease at home and abroad generally exist. Therefore, the composition and the health supplement thereof have significant effects of reducing blood sugar and blood fat, improving the hypercoagulable state of blood, dredging microcirculation, enhancing body immunity and reducing and relieving diabetic complications, and have important practical significance.
Disclosure of Invention
In view of the above, the invention provides a health-care composition for assisting in reducing blood sugar and blood fat and a health-care product thereof.
In order to achieve the above object, the present invention provides the following technical solutions:
the invention provides a health-care composition for assisting in reducing blood sugar and blood fat, which comprises spider silk hydrolyzed protein polypeptide, chromium chloride hexahydrate and chromium picolinate.
Spider silk hydrolyzed protein polypeptides: spider silk protein hydrolysate polypeptide contains 18 kinds of amino acids essential for human body. Compared with the general unhydrolyzed protein, the hydrolyzed protein polypeptide has higher and more comprehensive efficacy and is easier to be absorbed and utilized by the human body. Spider silk protein hydrolysate polypeptide has the functions of expanding blood vessels, improving microcirculation, increasing blood flow, promoting insulin secretion, regulating blood sugar and blood fat, reducing blood viscosity and the like.
Chromium chloride hexahydrate: chromium (Cr) is an essential trace element in the human body, and is involved in normal carbohydrate and lipid metabolism of the body and assists insulin in maintaining normal glucose tolerance. The Cr in the body of a diabetic patient is often in a deficiency state, and at present, a method for compensating the Cr element in the body by using chromium trichloride is researched and researched at home and abroad to reduce the blood sugar in the body and treat diabetes.
Chromium picolinate: chromium (Cr) is an important component of Glucose Tolerance Factor (GTF), and can increase the functional activity of insulin, participate in the synthesis of protein and the metabolism of nucleic acid and fat, enhance the insulin sensitivity in type 2 diabetes, lower blood sugar, inhibit fat, lose weight, supplement, strengthen muscles, strengthen body, improve immunity and improve the resistance of organisms to adverse conditions and stress conditions. Chromium picolinate (CrPic) is a complementary or alternative drug for type 2 diabetes that has an effect on glucose uptake through p38MAPK activation.
According to the invention, three active ingredients, namely the spider silk hydrolyzed protein polypeptide, chromium chloride hexahydrate and chromium picolinate are matched for use, and the three components are reasonably matched, so that an obvious synergistic effect is generated in the aspects of assisting blood sugar reduction and blood fat reduction.
In the composition, the content of small-molecule peptides below 2000Da in the spider silk hydrolyzed protein polypeptide is more than or equal to 90%.
In the invention, the spider silk hydrolysis protein polypeptide is prepared by the following method:
adding nitric acid water solution into spider silk for pre-digestion for 10h-16h, performing high-temperature high-pressure digestion at 110 ℃ for 3h-4h, and cooling to room temperature to obtain digestion liquid;
and adjusting the pH value of the digestion solution to 4-9, filtering, and collecting filtrate to obtain the spider silk protein hydrolysate polypeptide.
In some specific embodiments, the pre-digestion time is 12 hours, and the high-temperature high-pressure digestion time is 3 hours; the pH of the digestion solution is adjusted to 6.5.
In some embodiments, the volume fraction of the aqueous nitric acid solution used in the pre-digestion step is 50%.
In the specific embodiment of the invention, the adopted spider silks are derived from a spider culture base built by Hainan Wuzhishan and the pure natural spider silks produced by Jingzhao Chilobrachys jingzhao.
The spider silk hydrolyzed protein polypeptide is prepared by the method, the hydrolysis of the spider silk is complete, and the hydrolysis rate can reach over 90 percent; the hydrolysate is golden yellow and clear, is stored at room temperature for a long time and is stable without precipitation; the preparation process is simple, the industrial production is easy, and no harmful substance is left in the preparation process.
The protein content of the spider silk hydrolyzed protein obtained by the preparation method is more than 5mg/ml, and the protein content can be concentrated and adjusted according to special requirements; the micromolecules of the hydrolyzed polypeptide 1000D-2000D are more than 90%, the absorption is fast, and the effects of antioxidation, anti-aging, anti-inflammation, cell proliferation and the like, and safety experiments of skin irritation test, cytotoxicity and the like prove that the micromolecules have obvious effects and high safety, and are very suitable for wide application in the fields of biological medicine, medical treatment, cosmetology and the like. According to the invention, the spider silk hydrolyzed protein polypeptide prepared by the method is used in combination with chromium chloride hexahydrate and chromium picolinate, so that the obtained composition has more outstanding effects in assisting in reducing blood sugar and blood fat.
The invention also provides application of the health-care composition in preparing health-care products with the effects of reducing blood sugar and blood fat.
The invention also provides a health-care product with the effects of reducing blood sugar and blood fat, which comprises the health-care composition, vitamins, a zinc agent, a magnesium agent and auxiliary materials acceptable for health-care food.
In some embodiments, the vitamin comprises vitamin B1Vitamin B2Vitamin B3Vitamin B5Vitamin B6Vitamin B12Vitamin C, vitamin D3And folic acid.
The zinc agent is a zinc amino acid chelate.
The magnesium agent is magnesium oxide and/or magnesium amino acid chelate.
In some embodiments, the health product of the invention is prepared from the following raw materials in parts by weight:
5-20 parts of spider silk hydrolyzed protein polypeptide, 150-300 parts of chromium chloride hexahydrate, 80-160 parts of chromium picolinate and vitamin B14-8 parts of vitamin B26-10 parts of vitamin B330-40 parts of vitamin B55-8 parts of vitaminB65-8 parts of vitamin B120.015-0.019 parts, vitamin C20-40 parts and vitamin D30.003-0.005 part of folic acid, 0.06-0.09 part of magnesium oxide, 180 parts of magnesium oxide, 5-8 parts of magnesium amino acid chelate and 15-30 parts of zinc amino acid chelate.
Wherein, the percentage content of magnesium in the magnesium amino acid chelate is 10 percent, namely, 7 mg of the magnesium amino acid chelate contains 0.7 mg of magnesium. The percentage of zinc in the zinc amino acid chelate is 20%, that is, 20 mg of zinc amino acid chelate contains 4 mg of zinc, and the invention is not particularly limited to the specific type and source of the above chelate.
In some specific embodiments, the health product is prepared from the following raw materials in parts by weight:
20 parts of spider silk hydrolyzed protein polypeptide, 300 parts of chromium chloride hexahydrate, 160 parts of chromium picolinate and vitamin B16 portions of vitamin B28 portions of vitamin B335 portions of vitamin B57 portions of vitamin B67 portions of vitamin B120.017 parts of vitamin C30 parts of vitamin D30.0035 parts, 0.07 part of folic acid, 166 parts of magnesium oxide, 7 parts of magnesium amino acid chelate and 20 parts of zinc amino acid chelate.
In some embodiments, the health care composition is prepared from the following raw materials in parts by weight:
5 parts of spider silk hydrolyzed protein polypeptide, 150 parts of chromium chloride hexahydrate, 80 parts of chromium picolinate and vitamin B18 portions of vitamin B26 portions of vitamin B340 portions of vitamin B55 portions of vitamin B68 portions of vitamin B120.015 parts, vitamin C40 parts and vitamin D30.003 part, 0.09 part of folic acid, 140 parts of magnesium oxide, 8 parts of magnesium amino acid chelate and 15 parts of zinc amino acid chelate.
In some embodiments, the health care composition is prepared from the following raw materials in parts by weight:
10 parts of spider silk hydrolyzed protein polypeptide, 256 parts of chromium chloride hexahydrate, 134 parts of chromium picolinate and vitamin B14 parts of vitamin B210 portions of vitamin B330 portions of vitamin B58 portions of vitamin B65 portions of vitamin B120.019 part, vitamin C20 part and vitamin D30.005 part, 0.06 part of folic acid, 180 parts of magnesium oxide, 5 parts of magnesium amino acid chelate and 30 parts of zinc amino acid chelate.
The composition can be prepared into common dosage forms with pharmaceutically acceptable auxiliary materials which are common in the field, and the dosage forms of the medicine are capsules, paste, granules, oral liquid, tablets or dropping pills. Can also be made into other various dosage forms by selecting appropriate adjuvants according to actual needs.
The composition provided by the invention comprises spider silk hydrolyzed protein polypeptide, chromium chloride hexahydrate and chromium picolinate. According to the invention, the spider silk hydrolyzed protein polypeptide, the chromium chloride hexahydrate and the chromium picolinate are used in a matching manner, so that the obtained composition has the effects of remarkably assisting in reducing blood sugar and blood fat, is superior to the effects of using two components in pairs, and shows that the combination of the three components produces an obvious synergistic effect. On the basis, vitamins, zinc agents and magnesium agents are further added to prepare the health-care product, and the obtained health-care product has obvious effects of assisting in reducing blood sugar and blood fat.
Detailed Description
The invention provides a health-care composition for assisting in reducing blood sugar and blood fat and a health-care product thereof. Those skilled in the art can modify the process parameters appropriately to achieve the desired results with reference to the disclosure herein. It is expressly intended that all such similar substitutes and modifications which would be obvious to one skilled in the art are deemed to be included in the invention. While the methods and applications of this invention have been described in terms of preferred embodiments, it will be apparent to those of ordinary skill in the art that variations and modifications in the methods and applications described herein, as well as other suitable variations and combinations, may be made to implement and use the techniques of this invention without departing from the spirit and scope of the invention.
The test materials adopted by the invention are all common commercial products and can be purchased in the market.
The invention is further illustrated by the following examples:
compositions of examples 1 to 3
The composition of the compositions is shown in table 1.
TABLE 1
Wherein, the natural spider silk hydrolyzed protein polypeptide is prepared by the following method:
(1) accurately weighing 1g of spider silk, adding 5ml of nitric acid and 5ml of purified water, placing in a polytetrafluoroethylene digestion tank with the volume of 50ml, and performing pre-digestion for 12 hours; secondly, after the digestion tank is installed and sealed, the digestion tank is placed in an electric oven for digestion at 110 ℃ for 3 hours at high temperature and high pressure, cooled to room temperature, taken out, and then the volume is determined to be 100ml by purified water; neutralizing the ground product with 0.1g/ml KOH until the pH is 6.5; and fourthly, filtering the solution by double layers of quick filter paper to obtain clear bright yellow solution, namely the hydrolyzed protein polypeptide of the natural spider silk without precipitation.
Health products of examples 4 to 6
The health product comprises the following components:
TABLE 2
Note: per 100ml content; the recommended usage amount is: 100 ml/day.
Comparative examples 1 to 3
Comparative example 1: lack of native spider silk protein hydrolysate polypeptides, other components are unchanged;
comparative example 2: 130 parts of chromium chloride hexahydrate, less than 150 parts of chromium chloride hexahydrate and unchanged other components;
comparative example 3: 65 parts of chromium picolinate which is lower than 80 parts of chromium picolinate, and the other components are unchanged.
TABLE 3
Efficacy test 1 hypolipidemic test
(1) SD rats 90, female, 160-.
(2) Normal group: 10 were used as normal group, and basal diet was continued for 4 weeks;
(3) model group: 80 were used as model groups and fed with high-fat and high-sugar feed (base feed 59%, sucrose 20%, lard 12%, egg yolk powder 6%, cholesterol 2%, sodium cholate 1%) for 4 weeks. After 4 weeks, fasting for 12h, the model group was molded by intraperitoneal injection at a dose of 100mg/kg Streptozotocin (STZ) and the normal group was injected with sodium citrate buffer. After 72h, measuring blood sugar, and modeling the group with blood sugar above 11mmol/L, namely successfully modeling the rat.
(4) Each of 10 rats successfully modeled was taken and subjected to a positive control group (simvastatin tablets, 10mg/kg/d), an experimental group 4(300mg/kg/d), an experimental group 5(300mg/kg/d), an experimental group 6 (300mg/kg/d), a comparative example 1(300mg/kg/d), a comparative example 2(300mg/kg/d), and a comparative example 3(300 mg/kg/d).
(5) Experimental groups: the drug of different experimental groups 1 is administrated by gavage for 1 time every day and is continuously fed for 4 weeks. During dosing, all rats were fed basal diet. After the last administration, after fasting for 12h, blood was taken from the tail and serum Total Cholesterol (TC), Triglyceride (TG), low-density lipoprotein (LDL-C) and high-density lipoprotein cholesterol (HDL-C) levels were measured.
(6) Blood lipid lowering experiment results (Table 4)
TABLE 4
Note: p < 0.05, P < 0.01 compared to model group.
The results in Table 4 show that after the administration of the products of examples 4-6 to the model mice for 4 weeks, the TC, TG and LDL-C levels in the serum are obviously reduced and the HDC-L level is obviously increased compared with the model group, which shows that the products of the examples can reduce the blood fat level. It was found by comparative examples 1-3 that absent the native spider silk protein hydrolysate polypeptide, less than 150 parts chromium chloride hexahydrate, or less than 80 parts chromium picolinate, the reduced levels of serum TC, TG, LDL-C were all lower than in the experimental group, and HDC-L did not rise significantly.
Efficacy test 2 hypoglycemic test
(1) SD rats 90, female, 160-.
(2) Normal group: 10 were used as normal group, and the basal diet was continued to feed;
(3) model group: 80 were used as model groups and fed with high-fat and high-sugar feed (base feed 59%, sucrose 20%, lard 12%, egg yolk powder 6%, cholesterol 2%, sodium cholate 1%) for 4 weeks. After 4 weeks, fasting for 12h, the model group was molded by intraperitoneal injection at a dose of 100mg/kg Streptozotocin (STZ) and the normal group was injected with sodium citrate buffer. After 72h, measuring blood sugar, and modeling the group with blood sugar above 11mmol/L, namely successfully modeling the rat.
(4) Positive control group: 80 model groups of rats, metformin hydrochloride tablets, 25mg/kg/d were taken.
(5) Experimental groups: 10 rats in each model group were taken and administered with 300mg/kg/d of the drug to different experimental groups by gavage for 1 time per day for 8 weeks. During dosing, all rats were fed basal diet. After the last medicine feeding, after fasting for 12h, cutting the tail to take blood, and determining the blood sugar level in an empty stomach.
(6) The normal group and the model group were administered with the same volume of physiological saline for 8 weeks, and the blood glucose value was measured on an empty stomach.
The test results are shown in Table 5.
TABLE 5
Note: p < 0.05, P < 0.01 compared to model group.
As seen from Table 5, the blood glucose levels in the model group increased significantly with the feeding time. With the experiment, the blood sugar level of the experimental rat is obviously reduced, the blood sugar reducing effect of the experimental group 6 is the best, and the blood sugar reducing level can basically reach the positive control group after the experimental rat is fed for 8 weeks. It was found by comparative examples 1-3 that absent the native spider silk hydrolyzed protein polypeptide, less than 150 parts chromium chloride hexahydrate, or less than 80 parts chromium picolinate, the blood glucose lowering levels of the comparative examples were significantly weaker than the examples.
The foregoing is only a preferred embodiment of the present invention, and it should be noted that it is obvious to those skilled in the art that various modifications and improvements can be made without departing from the principle of the present invention, and these modifications and improvements should also be considered as the protection scope of the present invention.
Claims (10)
1. A health care composition for assisting in reducing blood sugar and blood fat is characterized by comprising spider silk hydrolyzed protein polypeptide, chromium chloride hexahydrate and chromium picolinate.
2. The health composition of claim 1, wherein the content of small molecule peptides of 2000Da or less in the spider silk protein hydrolysate polypeptide is 90% or more.
The nutraceutical composition of claim 1, wherein the spider silk hydrolyzed protein polypeptide is prepared by a method comprising:
adding nitric acid water solution into spider silk for pre-digestion for 10h-16h, performing high-temperature high-pressure digestion at 110 ℃ for 3h-4h, and cooling to room temperature to obtain digestion liquid;
and adjusting the pH value of the digestion solution to 4-9, filtering, and collecting filtrate to obtain the spider silk protein hydrolysate polypeptide.
3. The nutraceutical composition of claim 2, wherein the aqueous nitric acid solution has a volume fraction of 50%.
4. Use of the health care composition as claimed in any one of claims 1 to 3 in the preparation of health care products with the efficacy of reducing blood sugar and blood fat.
5. A health product with effects of reducing blood sugar and blood fat, which is characterized by comprising the health composition of any one of claims 1-4, vitamins, zinc agent, magnesium agent and auxiliary materials acceptable for health food.
6. The nutraceutical of claim 5, wherein said vitamin comprises vitamin B1Vitamin B2Vitamin B3Vitamin B5Vitamin B6Vitamin B12Vitamin C, vitamin D3And folic acid.
7. The health product of claim 1, wherein the zinc agent is a zinc amino acid chelate; the magnesium agent is magnesium oxide and/or magnesium amino acid chelate.
8. The health product of claim 5, wherein the health composition is prepared from the following raw materials in parts by weight:
5-20 parts of spider silk hydrolyzed protein polypeptide, 150-300 parts of chromium chloride hexahydrate, 80-160 parts of chromium picolinate and vitamin B14-8 parts of vitamin B26-10 parts of vitamin B330-40 parts of vitamin B55-8 parts of vitamin B65-8 parts of vitamin B120.015-0.019 parts, 20-40 parts of vitamin C and vitamin D30.003-0.005 part of folic acid, 0.06-0.09 part of magnesium oxide, 180 parts of magnesium oxide, 5-8 parts of magnesium amino acid chelate and 15-30 parts of zinc amino acid chelate.
9. The health product of claim 6, wherein the health composition is prepared from the following raw materials in parts by weight:
20 parts of spider silk hydrolyzed protein polypeptide, 300 parts of chromium chloride hexahydrate, 160 parts of chromium picolinate and vitamin B16 portions of vitamin B28 portions of vitamin B335 portions of vitamin B57 portions of vitamin B67 portions of vitamin B120.017 parts of vitamin C30 parts of vitamin D30.0035 parts, 0.07 part of folic acid, 166 parts of magnesium oxide, 7 parts of magnesium amino acid chelate and 20 parts of zinc amino acid chelate.
10. The health product of claim 9, in the form of capsule, paste, granule, oral liquid, tablet or drop pill.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110490012.7A CN113170898A (en) | 2021-05-06 | 2021-05-06 | Health-care composition assisting in reducing blood sugar and blood fat and health-care product thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110490012.7A CN113170898A (en) | 2021-05-06 | 2021-05-06 | Health-care composition assisting in reducing blood sugar and blood fat and health-care product thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113170898A true CN113170898A (en) | 2021-07-27 |
Family
ID=76928857
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110490012.7A Pending CN113170898A (en) | 2021-05-06 | 2021-05-06 | Health-care composition assisting in reducing blood sugar and blood fat and health-care product thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113170898A (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101278736A (en) * | 2008-03-28 | 2008-10-08 | 西安力邦制药有限公司 | Balanced enteral total nutrient preparation suitable for nutrition support of Asian population |
| CN102488220A (en) * | 2011-11-28 | 2012-06-13 | 中哈福生物医药科技（上海）有限公司 | Hypoglycemic compound, its preparation method and health food with hypoglycemic function |
| CN102613453A (en) * | 2012-03-31 | 2012-08-01 | 中国科学院南海海洋研究所 | Marine organism type enteral nutrition preparation for diabetes patients, preparation method of marine organism type enteral nutrition preparation and application |
| CN108244657A (en) * | 2018-01-12 | 2018-07-06 | 海南蛛王药业有限公司 | A kind of method for hydrolysis of spider silk |
| CN109329910A (en) * | 2018-09-28 | 2019-02-15 | 青岛大学 | A kind of preparation method of spider silk composition oral liquid |
-
2021
- 2021-05-06 CN CN202110490012.7A patent/CN113170898A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101278736A (en) * | 2008-03-28 | 2008-10-08 | 西安力邦制药有限公司 | Balanced enteral total nutrient preparation suitable for nutrition support of Asian population |
| CN102488220A (en) * | 2011-11-28 | 2012-06-13 | 中哈福生物医药科技（上海）有限公司 | Hypoglycemic compound, its preparation method and health food with hypoglycemic function |
| CN102613453A (en) * | 2012-03-31 | 2012-08-01 | 中国科学院南海海洋研究所 | Marine organism type enteral nutrition preparation for diabetes patients, preparation method of marine organism type enteral nutrition preparation and application |
| CN108244657A (en) * | 2018-01-12 | 2018-07-06 | 海南蛛王药业有限公司 | A kind of method for hydrolysis of spider silk |
| CN109329910A (en) * | 2018-09-28 | 2019-02-15 | 青岛大学 | A kind of preparation method of spider silk composition oral liquid |
Non-Patent Citations (3)
| Title |
|---|
| 养生保健小课堂: "《糖尿病也有"天敌"，深山里的蜘蛛网能降血糖，一降还一个准》", 《百度》 * |
| 段久芳: "《天然高分子材料》", 31 March 2016 * |
| 王心如, 中国协和医科大学出版社 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103238897B (en) | Composite plant solid drink suitable for diabetic patients | |
| CN101180062B (en) | Compound preparation for treating diabetes mellitus | |
| TWI721248B (en) | Anti-fatigue composition used for increasing endurance performance | |
| CN102271698B (en) | Pharmaceutical composition and use for preparing medicament thereof | |
| US10894070B2 (en) | Drug compound for the control of blood glucose, blood lipids and weight | |
| CN101716182B (en) | Combined medicine containing metformin hydrochloride and vitamin B12 | |
| CN105079447A (en) | Health care product or medicine composition capable of relieving fatigue and enhancing immunity | |
| CN104905237A (en) | Inonotus obliquus composite electuary and production method thereof | |
| CN107223981B (en) | Composition containing soybean polypeptide argatroxin and preparation method thereof | |
| CN113170898A (en) | Health-care composition assisting in reducing blood sugar and blood fat and health-care product thereof | |
| CN107281386B (en) | Method for preparing medicine for treating hypertension by using dendrobium officinale and radish seeds and application | |
| CN104225228B (en) | A kind of Chinese medicine preparation for being used to adjust blood glucose | |
| CN103239461A (en) | Vitamin B complex injection and preparation method thereof | |
| CN1411838A (en) | Medicine for curing diabetes | |
| CN102334525B (en) | Health-care food for reducing blood sugar | |
| TWI676473B (en) | Uses of poria cocos epidermis extract, poricoic acid a, and poricoic acid b in regulating blood glucose level | |
| KR100827350B1 (en) | Herbal medicine composition for descending blood sugar | |
| CN1431002A (en) | Health care combination of propolis for reducing blood sugar and fat as well as method for mfg. its capsule | |
| WO2019218537A1 (en) | Chitosan composition and preparation method therefor | |
| CN104524411B (en) | A kind of compound preparation for being used to treat chronic liver disease hypoalbuminemia | |
| CN102613547A (en) | Diet therapy product capable of protecting heart and preparation method thereof | |
| CN102293817B (en) | Traditional Chinese medicine composition for reducing blood sugar and preparation method thereof | |
| CN113812552B (en) | Total nutrient solid beverage | |
| CN102716448A (en) | Chinese patent medicine and TCM decoction capable of effectively curing nausea and vomiting | |
| CN101822698A (en) | Method for preparing black fungus and pantotrichum hypoglycemic composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210727 |
|
| RJ01 | Rejection of invention patent application after publication |